|
Cardiology
Clinical efficacy of angiotensin receptor-neprilysin inhibitor in de novo heart failure with reduced ejection fraction
Su Yeong Park, Min Gyu Kong, Inki Moon, Hyun Woo Park, Hyung-Oh Choi, Hye Sun Seo, Yoon Haeng Cho, Nae-Hee Lee, Kwan Yong Lee, Ho-Jun Jang, Je Sang Kim, Ik Jun Choi, Jon Suh
Korean J Intern Med. 2023;38(5):692-703. Published online August 31, 2023
Background/Aims: We aimed to analyze the efficacy of angiotensin receptor-neprilysin inhibitor (ARNI) by the disease course of heart failure (HF).
Methods: We evaluated 227 patients with HF in a multi-center retrospective cohort that included those with left ventricular ejection fraction (LVEF) ≤..
|
|
|
Effects of renin-angiotensin system blockers on the risk and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with hypertension
Jinwoo Lee, Seong Jin Jo, Youngjin Cho, Ji Hyun Lee, Il-Young Oh, Jin Joo Park, Young-Seok Cho, Dong-Ju Choi
Korean J Intern Med. 2021;36(Suppl 1):S123-S131. Published online February 10, 2021
Background/Aims: There are concerns that the use of renin-angiotensin system (RAS) blockers may increase the risk of being infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or progressing to a severe clinical course after infection. This this study aimed to investigate the i..
|
|
|
Update on association between exposure to renin-angiotensin-aldosterone system inhibitors and coronavirus disease 2019 in South Korea
Jeongkuk Seo, Minkook Son
Korean J Intern Med. 2021;36(Suppl 1):S114-S122. Published online February 25, 2021
Background/Aims: Since the onset of the coronavirus disease 2019 (COVID-19) pandemic, there have been concerns about the association between exposure to renin-angiotensin-aldosterone system (RAAS) inhibitors and the risk and severity of COVID-19.
Methods: We performed a case-control study that util..
|
|
|
Nephrology
Effect of urinary angiotensinogen and high-salt diet on blood pressure in patients with chronic kidney disease: results from the Korean Cohort Study for Outcome in Patients with Chronic Kidney Disease (KNOW-CKD)
Ha Yeon Kim, Hong Sang Choi, Chang Seong Kim, Eun Hui Bae, Seong Kwon Ma, Su-Ah Sung, Seung Hyeok Han, Kook-Hwan Oh, Curie Ahn, Soo Wan Kim
Korean J Intern Med. 2021;36(3):659-667. Published online October 8, 2020
Background/Aims: This study aimed to investigate whether urinary angiotensinogen (UAGT) excretion was associated with elevated blood pressure in patients with chronic kidney disease (CKD) and to evaluate the relationship among blood pressure, intra-renal renin-angiotensin system (RAS) activity, and ..
|
|
|
Cardiology
Different therapeutic associations of renin-angiotensin system inhibitors with coronavirus disease 2019 compared with usual pneumonia
Hae-Young Lee, Juhee Ahn, Juhong Park, Chang Kyung Kang, Sung-Ho Won, Dong Wook Kim, Jong-Heon Park, Ki-Hyun Chung, Joon-Sung Joh, JI Hwan Bang, Cheong Hee Kang, Myoung-don Oh, Wook Bum Pyun; The Korean Society of Hypertension; The National Committee for Clinical Management of Emerging Infectious Diseases
Korean J Intern Med. 2021;36(3):617-628. Published online April 16, 2021
Background/Aims: Although it is near concluded that renin-angiotensin system inhibitors do not have a harmful effect on coronavirus disease 2019 (COVID-19), there is no report about whether angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) offer any protective..
|
|
|
Pulmonology
Effect of angiotensin converting enzyme inhibitor and angiotensin II receptor blocker on the patients with sepsis
Hyun Woo Lee, Jae Kyung Suh, Eunjin Jang, Sang-Min Lee
Korean J Intern Med. 2021;36(2):371-381. Published online April 9, 2020
Background/Aims: Inhibitors of the renin-angiotensin system, angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs), reportedly have anti-inflammatory effects. This study assessed the association of prior use of ACE inhibitors and ARBs with sepsis-related clinical..
|
|
|
Angiotensin-converting enzyme 2 and kidney diseases in the era of coronavirus disease 2019
Sang Heon Suh, Seong Kwon Ma, Soo Wan Kim, Eun Hui Bae
Korean J Intern Med. 2021;36(2):247-262. Published online October 16, 2020
In the decades since the discovery of angiotensin-converting enzyme 2 (ACE2), its protective role in terms of antagonizing activation of the classical renin-angiotensin system (RAS) axis has been recognized in clinical and experimental studies on kidney and cardiovascular diseases. The effects of AC..
|
|
|
Cardiology
Fimasartan, an angiotensin II receptor antagonist, ameliorates an in vivo zebrafish model of heart failure
Hailian Quan, Gyu Chul Oh, Seung Hyeok Seok, Hae-Young Lee
Korean J Intern Med. 2020;35(6):1400-1410. Published online March 13, 2020
Background/Aims: Angiotensin II in the failing heart initially helps to maintain cardiac output and blood pressure, but ultimately accelerates its deterioration. In this study, we established a model of arrhythmia-induced heart failure (HF) in zebrafish and investigated the role of renin-angiotensi..
|
|
|
Angiotensin receptor-neprilysin inhibitor for the treatment of heart failure: a review of recent evidence
Hong-Mi Choi, Mi-Seung Shin
Korean J Intern Med. 2020;35(3):498-513. Published online April 29, 2020
Heart failure (HF) is a growing health concern in aging societies worldwide. Sacubitril/valsartan is changing the real-world treatment in the whole spectrum of HF. The beginning was the PARADIGM-HF trial published in 2014, which demonstrated the beneficial effects of inhibiting natriuretic peptide b..
|
|
|
Cardiology
Olmesartan is not associated with the risk of enteropathy: a Korean nationwide observational
cohort study
Seng Chan You, Hojun Park, Dukyong Yoon, Sooyoung Park, Boyoung Joung, Rae Woong Park
Korean J Intern Med. 2019;34(1):90-98. Published online November 27, 2017
Background/Aims: Olmesartan, a widely used angiotensin II receptor blocker (ARB), has been linked to sprue-like enteropathy. No cases of olmesartan-associated enteropathy have been reported in Northeast Asia. We investigated the associations between olmesartan and other ARBs and the incidence of ent..
|
|
|
Gastroenterology
Role of the renin-angiotensin system in hepatic fibrosis and portal hypertension
Kwang Yong Shim, Young Woo Eom, Moon Young Kim, Seong Hee Kang, Soon Koo Baik
Korean J Intern Med. 2018;33(3):453-461. Published online February 21, 2018
The renin-angiotensin system (RAS) is an important regulator of cirrhosis and portal hypertension. As hepatic fibrosis progresses, levels of the RAS components angiotensin (Ang) II, Ang-(1–7), angiotensin-converting enzyme (ACE), and Ang II type 1 receptor (AT1R) are increased. The primary effector ..
|
|
|
Cardiology
24-Hour blood pressure response to lower dose (30 mg) fimasartan in Korean patients with mild to moderate essential hypertension
Hae-Young Lee, Cheol-Ho Kim, Jae-Kwan Song, Shung Chull Chae, Myung Ho Jeong, Dong-Soo Kim, Byung-Hee Oh
Korean J Intern Med. 2017;32(6):1025-1036. Published online October 17, 2017
Background/Aims: Fimasartan is an angiotensin type 1 receptor blocker (ARB) which has comparable efficacy and tolerability with other ARBs. The aim of this study was to evaluate 24-hour blood pressure (BP) lowering efficacy and the tolerability of the low dose fimasartan compared with valsartan in p..
|
|
|
Nephrology
Effect of low-dose valsartan on proteinuria in normotensive immunoglobulin A nephropathy with minimal proteinuria: a randomized trial
Young-Il Jo, Ha-Young Na, Ju-Young Moon, Sang-Woong Han, Dong-Ho Yang, Sang-Ho Lee, Hyeong-Cheon Park, Hoon-Young Choi, So-Dug Lim, Jeong-Hae Kie, Yong-Kyu Lee, Sug-Kyun Shin
Korean J Intern Med. 2016;31(2):335-343. Published online February 15, 2016
Background/Aims: Immunoglobulin A nephropathy (IgAN) is a generally progressive disease, even in patients with favorable prognostic features. In this study, we aimed to investigate the antiproteinuric effect and tolerability of low-dose valsartan (an angiotensin II receptor blocker) therapy in normo..
|
|
|
Concomitant inhibition of renin angiotensin system and Toll-like receptor 2 attenuates renal
injury in unilateral ureteral obstructed mice
Sarah Chung, Jin Young Jeong, Yoon Kyung Chang, Dae Eun Choi, Ki Ryang Na, Beom Jin Lim, Kang Wook Lee
Korean J Intern Med. 2016;31(2):323-334. Published online February 26, 2016
Background/Aims: There has been controversy about the role of Toll-like receptor 2 (TLR2) in renal injury following ureteric obstruction. Although inhibition of the renin angiotensin system (RAS) reduces TLR2 expression in mice, the exact relationship between TLR2 and RAS is not known. The aim of th..
|
|
|
Cardiology
Angiotensin II type 1 receptor blockers as a first choice in patients with acute myocardial infarction
Jang Hoon Lee, Myung Hwan Bae, Dong Heon Yang, Hun Sik Park, Yongkeun Cho, Won Kee Lee, Myung Ho Jeong, Young Jo Kim, Myeong Chan Cho, Chong Jin Kim, Shung Chull Chae, Korea Acute Myocardial Infarction Registry Investigators
Korean J Intern Med. 2016;31(2):267-276. Published online December 23, 2015
Background/Aims: Angiotensin II type 1 receptor blockers (ARBs) have not been adequately evaluated in patients without left ventricular (LV) dysfunction or heart failure after acute myocardial infarction (AMI).
Methods: Between November 2005 and January 2008, 6,781 patients who were not receiving a..
|
|
|
Nephrology
Angiotensin III increases monocyte chemoattractant protein-1 expression in cultured human proximal tubular epithelial cells
Hyung Wook Kim, Young Ok Kim, Sun Ae Yoon, Jeong-Sun Han, Hyun-Bae Chun, Young Soo Kim
Korean J Intern Med. 2016;31(1):116-124. Published online December 28, 2015
Background/Aims: We investigated whether angiotensin III (Ang III) is involved in monocyte recruitment through regulation of the chemokine monocyte chemoattractant protein-1 (MCP-1) in cultured human proximal tubular epithelial cells (HK-2 cells).
Methods: We measured MCP-1 levels in HK-2 cells tha..
|
|
|
The renin-angiotensin system and aging in the kidney
Hye Eun Yoon, Bum Soon Choi
Korean J Intern Med. 2014;29(3):291-295. Published online April 29, 2014
Aging is associated with progressive functional deterioration and structural changes in the kidney. Changes in the activity or responsiveness of the renin-angiotensin system (RAS) occur with aging. RAS changes predispose the elderly to various fluid and electrolyte imbalances as well as acute kidney..
|
|
|
Cardiology
Effect of renin-angiotensin-system blockers on contrast-medium-induced acute kidney injury after coronary angiography
Ja-Jun Goo, Jae-Joon Kim, Ji-Hoon Kang, Kyoung-Nyoun Kim, Ki-Sup Byun, Mi-kyung Kim, Tae-Ik Kim
Korean J Intern Med. 2014;29(2):203-209. Published online February 27, 2014
Background/Aims: With the increasing incidence of cardiovascular disease, angiocardiography using contrast-enhancing media has become an essential diagnostic and therapeutic tool, despite the risk of contrast-medium-induced acute kidney injury (CIAKI). CIAKI may be exacerbated by renin-angiotensin-s..
|
|
|
Nephrology
Additional antihypertensive effect of magnesium supplementation with an angiotensin II receptor blocker in hypomagnesemic rats
Kyubok Jin, Tae Hee Kim, Yeong Hoon Kim, Yang Wook Kim
Korean J Intern Med. 2013;28(2):197-205. Published online February 27, 2013
Background/AimsMagnesium (Mg) is an essential element for vascular function and blood pressure regulation. Several studies have demonstrated that Mg concentration is inversely associated with blood pressure, and that Mg supplementation attenuates hypertension. The purpose of t..
|
|
|
PPARγ Agonist Beyond Glucose Lowering Effect
Akira Sugawara, Akira Uruno, Masataka Kudo, Ken Matsuda, Chul Woo Yang, Sadayoshi Ito
Korean J Intern Med. 2011;26(1):19-24. Published online March 2, 2011
The nuclear hormone receptor PPARγ is activated by several agonists, including members of the thiazolidinedione group of insulin sensitizers. Pleiotropic beneficial effects of these agonists, independent of their blood glucose-lowering effects, have recently been demonstrated in the vasculature...
|
|
|
